Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review.
TNM
adjuvant
breast cancer
chemotherapy
consensus
ctDNA
endocrine therapy
genomic signature
hormone receptors
risk of relapse
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Apr 2022
09 Apr 2022
Historique:
received:
14
02
2022
revised:
06
04
2022
accepted:
06
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. During the past three decades, several improvements in the adjuvant treatment of hormone receptor-positive/HER2-negative breast cancer have been achieved with the introduction of optimized adjuvant chemotherapy and endocrine treatment. However, estimating the risk of relapse of breast cancer on an individual basis is still challenging. The IRIDE (hIGh Risk DEfinition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormone-positive/HER2-negative early breast cancer relapse. A panel of experts in breast cancer was involved in identifying clinical, pathological, morphological, and genetic factors. A RAND consensus method was used to define the relevance of each risk factor. Among the 21 features included, 12 were considered relevant risk factors for relapse. For each of these, we provided a consensus statement and relevant comments on the supporting scientific evidence. This work may guide clinicians in the practical management of hormone-positive/HER2-negative early breast cancers.
Identifiants
pubmed: 35454806
pii: cancers14081898
doi: 10.3390/cancers14081898
pmc: PMC9029479
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Clin Oncol. 2006 Mar 1;24(7):1037-44
pubmed: 16505422
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
NPJ Breast Cancer. 2017 Sep 8;3:33
pubmed: 28900633
Breast Cancer Res Treat. 1992;22(3):207-19
pubmed: 1391987
Eur J Radiol. 2007 Jan;61(1):158-62
pubmed: 16987629
J Clin Oncol. 2020 Dec 1;38(34):3987-3998
pubmed: 32954927
Nat Rev Dis Primers. 2019 Sep 23;5(1):66
pubmed: 31548545
Arch Pathol Lab Med. 2000 Jul;124(7):966-78
pubmed: 10888772
Am J Surg. 2009 May;197(5):674-7
pubmed: 18789411
N Engl J Med. 2004 Dec 30;351(27):2817-26
pubmed: 15591335
Cancer. 2008 Apr 1;112(7):1437-44
pubmed: 18286526
J Natl Cancer Inst. 2006 Feb 15;98(4):262-72
pubmed: 16478745
Lancet. 2019 Apr 6;393(10179):1440-1452
pubmed: 30739743
Clin Cancer Res. 2006 Aug 1;12(15):4614-8
pubmed: 16899609
Br J Cancer. 2010 Jul 27;103(3):297-302
pubmed: 20606681
J Clin Oncol. 2016 Jul 10;34(20):2341-9
pubmed: 26926676
Oncologist. 2017 Nov;22(11):1292-1300
pubmed: 28592619
J Clin Oncol. 2020 Apr 20;38(12):1258-1267
pubmed: 31618128
J Clin Oncol. 2008 Feb 10;26(5):729-35
pubmed: 18258980
Oncol Rev. 2017 Mar 10;11(1):317
pubmed: 28382188
Ann Oncol. 2011 Oct;22(10):2201-7
pubmed: 21335417
Lancet. 2012 Feb 4;379(9814):432-44
pubmed: 22152853
J Clin Oncol. 2020 Apr 20;38(12):1346-1366
pubmed: 31928404
Ann Oncol. 2007 May;18(5):859-67
pubmed: 17301074
Cancers (Basel). 2021 Sep 03;13(17):
pubmed: 34503265
Lancet Oncol. 2021 Apr;22(4):476-488
pubmed: 33721561
J Clin Oncol. 2015 Mar 10;33(8):916-22
pubmed: 25332252
Br J Cancer. 2013 Dec 10;109(12):2959-64
pubmed: 24157828
Lancet. 2015 Oct 3;386(10001):1341-1352
pubmed: 26211827
Future Oncol. 2019 Jan;15(2):207-224
pubmed: 30156427
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
N Engl J Med. 2016 Aug 25;375(8):717-29
pubmed: 27557300
JAMA Oncol. 2018 Apr 01;4(4):545-553
pubmed: 29450494
Oncotarget. 2021 Apr 27;12(9):936-947
pubmed: 33953847
J Clin Oncol. 2010 Apr 10;28(11):1829-34
pubmed: 20212256
Am J Surg. 2004 Apr;187(4):528-32
pubmed: 15041505
Am Soc Clin Oncol Educ Book. 2018 May 23;38:38-46
pubmed: 30231409
N Engl J Med. 2018 Jul 12;379(2):111-121
pubmed: 29860917
Ann Oncol. 2015 Jul;26(7):1280-91
pubmed: 26019189
N Engl J Med. 2015 Nov 19;373(21):2005-14
pubmed: 26412349
Br J Cancer. 2007 May 21;96(10):1504-13
pubmed: 17453008
Surg Clin North Am. 2018 Aug;98(4):687-702
pubmed: 30005768
J Clin Oncol. 2003 Apr 1;21(7):1205-13
pubmed: 12663706
CA Cancer J Clin. 2017 Jul 8;67(4):290-303
pubmed: 28294295
N Engl J Med. 2017 Nov 9;377(19):1836-1846
pubmed: 29117498
J Natl Cancer Inst. 2006 Nov 1;98(21):1571-81
pubmed: 17077359
Cancer. 2005 May 15;103(10):2006-14
pubmed: 15812825
J Clin Pathol. 1993 Feb;46(2):189-90
pubmed: 8459046
J Clin Oncol. 2007 Oct 1;25(28):4414-22
pubmed: 17785706
Am J Clin Pathol. 1995 Feb;103(2):195-8
pubmed: 7856562
NPJ Breast Cancer. 2021 Jun 28;7(1):82
pubmed: 34183674
J Clin Oncol. 2013 Aug 1;31(22):2783-90
pubmed: 23816962
Breast Cancer Res Treat. 2008 Oct;111(3):541-7
pubmed: 18026874
Hum Pathol. 1989 Aug;20(8):758-64
pubmed: 2545592
NPJ Breast Cancer. 2021 Aug 2;7(1):101
pubmed: 34341356
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
Histopathology. 2020 Aug;77(2):181-185
pubmed: 32056259
Curr Med Res Opin. 2013 Nov;29(11):1453-61
pubmed: 23927551
N Engl J Med. 2019 Jun 20;380(25):2395-2405
pubmed: 31157962
Breast Cancer Res Treat. 2015 Oct;153(3):477-91
pubmed: 26341751
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Ann Oncol. 2014 Feb;25(2):339-45
pubmed: 24347518
J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92
pubmed: 16954471
Oncologist. 2020 Sep;25(9):e1355-e1362
pubmed: 32618068
N Engl J Med. 2002 Dec 19;347(25):1999-2009
pubmed: 12490681
J Clin Oncol. 2007 Sep 1;25(25):3846-52
pubmed: 17679725
J Clin Oncol. 2017 Apr 1;35(10):1049-1060
pubmed: 28135148
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
J Natl Cancer Inst. 2013 Oct 2;105(19):1504-11
pubmed: 24029245
Lancet Oncol. 2010 Jan;11(1):55-65
pubmed: 20005174
J Pathol. 2008 Oct;216(2):141-50
pubmed: 18720457
Lancet. 2011 Aug 27;378(9793):771-84
pubmed: 21802721
Ann Oncol. 2013 Mar;24(3):640-7
pubmed: 23035151
N Engl J Med. 2021 Jun 24;384(25):2394-2405
pubmed: 34081848
Breast Cancer Res Treat. 2017 Jun;163(2):303-310
pubmed: 28243896
N Engl J Med. 2018 Jul 12;379(2):122-137
pubmed: 29863451
Breast Cancer Res Treat. 2020 Jun;181(3):667-678
pubmed: 32356254
Arch Pathol Lab Med. 2014 Aug;138(8):1048-52
pubmed: 25076293
Clin Cancer Res. 2011 Sep 15;17(18):6012-20
pubmed: 21807638
Breast. 2008 Aug;17(4):323-34
pubmed: 18455396
J Clin Oncol. 2010 Jan 1;28(1):99-104
pubmed: 19917872
J Natl Cancer Inst. 2021 Jul 1;113(7):808-819
pubmed: 33369635
Int J Cancer. 2000 Mar 20;89(2):111-7
pubmed: 10754487